The GAD-2 is an ultra-brief screen for anxiety consisting of the first two items of the GAD-7: how often, over the past two weeks, the person has been bothered by feeling nervous, anxious or on edge, and by not being able to stop or control worrying. Each item is scored 0 (not at all) to 3 (nearly every day), giving a total of 0-6. The two items capture the core cognitive engine of generalised anxiety - anxious affect and uncontrollable worry.
Although built around generalised anxiety disorder, the GAD-2 performs respectably as a first-pass case-finder for the other common anxiety disorders too, including panic disorder, social anxiety disorder and PTSD, albeit with somewhat lower sensitivity than for GAD. It answers one question quickly: does this person need a fuller anxiety assessment?
02 - Origin & purpose
Where it comes from.
The GAD-2 was introduced by Kurt Kroenke, Robert Spitzer and colleagues in 2007, in a large primary-care study of nearly 1,000 patients that examined the prevalence, impairment and detection of anxiety disorders. Rather than writing new items, they took the two highest-performing items of the GAD-7 - itself published the year before - and showed that this two-item core retained most of the parent scale's screening accuracy.
The purpose was pragmatic: primary care needs case-finding tools that take seconds, not minutes. The GAD-2 slots into busy intake flows, and pairs with the PHQ-2 to form the PHQ-4, a four-item combined screen for depression and anxiety. Like the whole PHQ/GAD family, it was developed with an educational grant from Pfizer but is free to use without permission.
03 - Scoring & cutoffs
How scoring works.
Both items are scored 0-3 and summed, giving a total of 0-6. A score of 3 or greater is the standard positive screen. In the original validation this cutoff identified generalised anxiety disorder with 86% sensitivity and 83% specificity; accuracy for other anxiety disorders is somewhat lower. A positive screen is not a diagnosis - it is a prompt to administer the full GAD-7 and, where indicated, a diagnostic interview.
Score
Severity
Interpretation
0–2
Negative screen
Below the cutoff. Anxiety is unlikely on this screen.
3–6
Positive screen
At or above the cutoff of 3. Follow up with the GAD-7 or a clinical interview.
04 - Validation evidence
How well it performs.
In Kroenke and colleagues' 2007 primary-care validation, the GAD-2 at a cutoff of 3 showed 86% sensitivity and 83% specificity for generalised anxiety disorder against a structured diagnostic interview. A 2016 systematic review and diagnostic meta-analysis by Plummer and colleagues pooled the available studies and found somewhat more conservative figures - pooled sensitivity 0.76 and specificity 0.81 at the same cutoff - while confirming that 3 offers the best balance of sensitivity and specificity. Validation studies in other languages and settings have reported strong discrimination, including an area under the ROC curve of 0.94 and Cronbach's alpha of 0.88 in a large Spanish primary-care validation.
86% / 83%
SENSITIVITY / SPECIFICITY FOR GAD AT CUTOFF ≥3 (KROENKE ET AL., 2007)
0.76 / 0.81
POOLED SENSITIVITY / SPECIFICITY AT ≥3 (PLUMMER ET AL., 2016 META-ANALYSIS)
0.94
AUC IN THE SPANISH PRIMARY-CARE VALIDATION (GARCÍA-CAMPAYO ET AL., 2012)
<30 seconds
2 ITEMS - BRIEF ENOUGH FOR UNIVERSAL INTAKE SCREENING
05 - How it compares
How it compares to the alternatives.
Instrument
Items
Time
When to reach for it
GAD-2
2
<30 sec
Universal first-pass anxiety screening at intake; positive screens step up to the GAD-7.
Somatic-heavy anxiety symptom inventory; licensed (Pearson), unlike the free GAD-2.
06 - When to use it
Right tool, wrong tool.
Reach for it when
-Universal or high-volume screening at intake, where every extra item has a cost.
-Case-finding in primary care and general medical settings where anxiety is easily missed.
-As the anxiety half of the PHQ-4 when paired with the PHQ-2.
-A quick check when anxiety is suspected mid-consultation and you need a defensible reason to assess further.
Reach for something else when
-Grading severity or monitoring change over treatment - the 0-6 range is far too coarse; use the GAD-7.
-Diagnosing any anxiety disorder; a positive screen only warrants further assessment.
-Ruling out panic disorder, social anxiety or PTSD when clinical suspicion is specific - sensitivity for non-GAD disorders is lower, so use a targeted instrument.
-Risk assessment; the GAD-2 asks nothing about self-harm.
07 - Confidence & precision
Reading the score with care.
With only two items and a seven-point range, the GAD-2 is deliberately coarse. No standard error of measurement or minimal clinically important difference is established for it, and single-point changes should carry no clinical weight. It should be read categorically - below or at-and-above the cutoff of 3 - rather than as a severity dial. When a positive screen needs quantifying, or change needs tracking, step up to the GAD-7, which has established severity bands and change conventions.
08 - Limitations
What it cannot tell you.
- Too coarse for severity grading or outcome monitoring; it is a gate, not a gauge.
- Sensitivity is lower for panic disorder, social anxiety disorder and PTSD than for GAD, so a negative screen does not exclude them when suspicion is specific.
- Pooled real-world accuracy (sensitivity 0.76) is lower than the original validation suggested; a meaningful minority of cases screen negative.
- The two-week window can miss episodic or situational anxiety.
- Self-report; scores depend on recognition and willingness to disclose.
- No risk content - never a substitute for asking about suicidality.
See how Aisel removes friction where it costs most. A 20-minute walkthrough tailored to your clinic.
We value your privacy
We use cookies to analyse site usage and improve your experience. Analytics and embedded media (e.g. YouTube) only load if you accept. Read our cookie policy.